Introduction
Atrial fibrillation (AF) is the most prevalent cardiac arrhythmia and it is estimated that every fourth middle-aged adult will ultimately develop AF during their lifespan.
1 Electrical cardioversion (CV) has remained the cornerstone of rhythm control management of AF for decades and is widely used in symptomatic patients despite the lack of evidence of any survival benefit. [2] [3] [4] In previous studies longer duration of AF episode increased the possibility of unsuccessful CV and stroke. [5] [6] [7] However, little is known on efficacy and safety of CV with different AF episode lengths in patients on oral anticoagulation. Therefore, we sought to investigate the optimal timing of CV for AF in this multi-center study.
Methods
The FinCV studies constitute an observational study program exploring thrombotic and bleeding complications of AF after electrical CV. [6] [7] [8] [9] The present study cohort was gathered from datasets of the FinCV 
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FinCV3 studies, respectively. The details of the catchment areas of each study have been described in detail previously. 7, 8, 10 Initially patient registries were screened in each hospital for ICD10 code I48 (AF) and for Nordic Classification of Surgical Procedures code TFP20 (cardioversion). Patients were then included in each study according to specified inclusion criteria: all patients admitted to emergency room because of an acute (<48h) AF in whom electrical or pharmacological CV was attempted (FinCV), all patients with persistent (>48h) AF in whom elective electrical CV was attempted (FinCV2) and all patients with AF using non-vitamin K oral anticoagulants (NOAC) in whom electrical or pharmacological CV was attempted (FinCV3). Altogether these studies comprised 5441 patients and 10852 CVs. All patient data was collected from patient records using a structured electronic case report form consisting of general disease and AF history and medications.
The primary end point of this study was a composite adverse outcome defined as the occurrence of any of the following events: death, thromboembolic event, unsuccessful CV, acute arrhythmic complication and/or AF recurrence within the 30-day follow-up. The inability to maintain sinus rhythm until discharge despite initially successful CV was considered an unsuccessful CV. Asystole lasting longer than 5 seconds, ventricular tachycardia or ventricular fibrillation immediately after
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Accepted Article the CV were considered acute arrhythmic complications. A thromboembolic event was classified as an ischemic non-hemorrhagic stroke adjudicated by the treating neurologist and imaging.
Occurrence of AF within 30 days after a successful index CV confirmed by ECG or pacemaker log was defined as an AF recurrence. 
test was used to estimate the calibration of the regression models. All tests were two-sided and p<0.05 was considered statistically significant. IBM SPSS Statistics software version 22.0 was used to perform all analyses.
Results
Altogether 1767, 516, 632 and 1441 CVs were performed for index AF episode lasting <24h, 24h-48h, 48h -30d, >30d, respectively. Baseline characteristics of each patient group are depicted in Table 1 . Patients with shorter (<24h or 24h-48h) index AF episode duration were more likely to be women and have a history of hypertension, coronary artery disease, peripheral artery disease, prior stroke or myocardial infarction or antiarrhythmic medication. Patients with longer (48h-30d or >30d) AF episodes had lower CHA 2 DS 2 -VASc-scores and ventricular rate at the time of CV, but were more likely to have a history of congestive heart failure or chronic kidney disease.
The associations between index AF episode duration and adverse outcomes are summarized in Table 2 In an additional analysis, the study patient cohort with known duration of the index AF episode was compared with the excluded patient cohort with uncertain duration of the index AF episode (Supplementary Table S1 ). The patients with AF episodes of uncertain duration were generally healthier, more often women and had less often prior history of AF or medications. The rate of unsuccessful CVs was higher (17.5% vs 10.3%, p<0.01), but fewer (0.1% vs 0.7%, p=0.03) episodes of asystole lasting >5 seconds occurred in the excluded patient cohort compared to the study patient cohort. There were no other differences between the groups in the other efficacy or safety end points of the composite adverse outcome.
Discussion
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The present large multi-center study demonstrated that the risk for adverse outcomes after CV was doubled in patients with AF episode longer than 48h when compared to patients with a shorter duration of AF before CV irrespective of other predictors of CV failure and complications.
Concordantly, rates of unsuccessful CVs and recurrences of AF within 30 days of follow-up after CV were lowest in the patient group with AF episode lasting 24-48h. The occurrence of safety end points i.e. thromboembolic events, mortality and episodes of asystole (>5 s) after CV was low and spread evenly among patient groups. These observations support the view that performing CV early is better than delay it when aiming at rhythm control.
It was not a surprise that there were less unsuccessful CVs among patients with acute AF episodes.
The overall rates of unsuccessful CVs and recurrences of AF within the 30-day follow-up were in line with previous studies. 5, [11] [12] [13] [14] The relationship between AF episode duration and rate of unsuccessful CV is also in agreement with previous studies 5, 7, 15 whereas the predictors for AF recurrence after CV have been inconsistent 11, [13] [14] [15] [16] and no association between the episode duration and recurrence rate of AF has been previously observed. However, prior studies were based on small patient populations and they were less balanced with respect to AF episode duration. Importantly, in our study only 5% of CVs performed for AF lasting 24-48h were unsuccessful, whereas the patient group with shortest AF episodes had slightly more unsuccessful CVs. Similarly, the recurrence rate of AF after CV was slightly lower in patients with AF lasting 24-48h when compared to patients with AF lasting <24h.
The rate of thromboembolic events, deaths and acute arrhythmic complications was scant and in line with prior studies 14, 17, 18 and these adverse events were not associated with AF episode duration. Prior studies have, however, suggested that elective CV of AF lasting >48h introduces patients to five-fold risk (~ 0.5% for the post-CV month) for thromboembolic events despite
anticoagulation compared to overall low risk in patients on oral anticoagulation (0.1%/month).
Although recent data suggests that this extra risk associated with elective CV of AF lasting >48h could be countered with more intensive anticoagulation 19 , non-anticoagulated AF patients should be referred for prompt (preferably <12h) rhythm conversion since shorter delay to CV has been tied to a lower risk of stroke 6 .
While there appears to be relatively little safety issues with the CV procedure itself in appropriately anticoagulated patients, there is substantially more room for improvement with efficacy outcomes after CV for AF. The composite adverse outcome was largely driven by the efficacy end points i.e. the rates of unsuccessful CV and recurrence of AF after CV. Modifiable independent risk factors for the composite adverse outcome were scarce and this further underscores the importance of minimizing the delay between AF diagnosis and CV in rhythm management of AF. This view is supported by the supplementary data analysis revealing lower efficacy outcomes in patients with AF episodes of unknown duration.
The major limitations of our study are related to the retrospective set-up. First, the inclusion of study population from three different cohorts may cause imbalance in the study cohort.
Nevertheless, patients were from the same hospitals and catchment areas, and CV procedures were performed using a standardized protocol. Second, the definition of index episode duration is subjective. This is why we excluded patients with unknown episode duration from the main analysis, but provided this data in the Supplement. Despite these limitations, we believe that this data can guide future research and treatment decisions in patients undergoing CV. 64 (10) 64 [12] 62 (12.1)
63 (11) 63 [14] 73 (12.7)
64 (10) 65 [14] Abbreviations: CV = cardioversion; AF = atrial fibrillation; VKA = vitamin-K antagonist; CHA 2 DS 2 -VASc = congestive heart failure, hypertension, age ≥ 75 years (doubled), diabetes mellitus, prior stroke, transient ischemic attack or thromboembolism (doubled), vascular disease, age 65 to 74 years and sex category (female, unless <65 years and no other risk factors). Values in parentheses are %.
Abbreviations: CV = cardioversion; AF = atrial fibrillation; H-L: Hosmer-Lemeshow test p-value.
